Olr125 inhibitors are a class of chemical compounds specifically designed to target and inhibit the Olr125 receptor, a member of the olfactory receptor family, which is part of the broader G protein-coupled receptor (GPCR) superfamily. These receptors play a critical role in the olfactory system by detecting odorant molecules and converting these chemical signals into neural impulses that are ultimately perceived as smells. Olr125 inhibitors function by binding to specific sites on the Olr125 receptor, such as the active site where natural ligands would typically bind or at allosteric sites that modulate receptor activity. By occupying these binding sites, the inhibitors prevent the receptor from undergoing the conformational changes necessary to initiate intracellular signaling pathways. This inhibition effectively disrupts the receptor's normal function, blocking the transmission of olfactory signals that would typically result from the binding of odorant molecules. The design and development of Olr125 inhibitors often rely on detailed structural studies of the receptor, using techniques such as X-ray crystallography, molecular dynamics simulations, and cryo-electron microscopy. These techniques provide crucial insights into the receptor's binding pockets and other critical regions, enabling the design of inhibitors that are both highly specific and effective in modulating the activity of the Olr125 receptor.
Chemically, Olr125 inhibitors exhibit a wide range of structures and properties, reflecting the diverse approaches used in their design and synthesis. These compounds can range from small, lipophilic molecules that easily penetrate cellular membranes to more complex structures that may require sophisticated synthetic techniques to achieve the desired binding affinity and specificity. The synthetic pathways used to create Olr125 inhibitors often involve multiple steps of organic synthesis, including the formation of molecular frameworks and the strategic incorporation of functional groups that enhance binding interactions with the receptor. After synthesis, these compounds undergo rigorous characterization using analytical techniques such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry, and high-performance liquid chromatography (HPLC) to ensure their structural integrity, purity, and inhibitory potency. The study of Olr125 inhibitors not only provides valuable insights into the specific mechanisms by which this olfactory receptor operates but also contributes to a broader understanding of GPCR modulation. This research is crucial for advancing knowledge of the molecular processes underlying sensory perception, particularly in the context of olfaction, and offers important insights into how olfactory receptors can be selectively targeted and regulated by small molecules.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK inhibitor, could disrupt the MAPK/ERK pathway potentially involving Olr125. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
MEK inhibitor, might affect cell signaling pathways relevant to Olr125's function. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
MET and VEGFR2 inhibitor, potentially impacts angiogenesis and pathways related to Olr125. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
mTOR inhibitor, can modulate cell growth and survival pathways possibly involving Olr125. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
CDK4/6 inhibitor, might impact cell cycle regulation pathways related to Olr125. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
RAF inhibitor, could affect multiple signaling pathways, influencing Olr125's activity. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
Multi-kinase inhibitor, could impact angiogenesis and signaling pathways involving Olr125. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor, might affect protein degradation processes involving Olr125. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
EGFR and HER2 inhibitor, potentially disrupts growth factor signaling pathways involving Olr125. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Src family kinase inhibitor, can modulate pathways where Olr125 may be involved. | ||||||